Related Experiment Video
Updated: Aug 1, 2026
15:23
Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Alzheimer's beta-amyloid peptide: affinity for metal chelates
R Balakrishnan1, R Parthasarathy, E Sulkowski
1Biophysics Department, Roswell Park Cancer Institute, Buffalo, New York, USA. rbalakri@cmgm.stanford.edu
Summary
Alzheimer's amyloid peptides bind to metal-chelating columns, with varying retention based on the metal ion and pH. Histidine clusters in the peptides likely mediate this high-affinity binding to immobilized metal ions.
Area of Science:
- Biochemistry
- Neuroscience
- Analytical Chemistry
Background:
- Alzheimer's disease is linked to amyloid-beta (A beta) peptides.
- Understanding A beta peptide interactions is crucial for diagnostics and therapeutics.
- Immobilized metal affinity chromatography (IMAC) is a powerful separation technique.
Purpose of the Study:
- To investigate the chromatographic behavior of Alzheimer's A beta peptides on immobilized metal affinity chromatography (IMAC) columns.
- To explore the role of histidine residues in A beta peptide binding to metal ions.
- To assess the potential of IMAC for A beta peptide separation and analysis.
Main Methods:
- Chromatographic separation of A beta(1-42), A beta(1-28), and A beta(1-16) peptides.
- Utilized immobilized metal affinity chromatography (IMAC) with IDA-M(II) columns (M = Cu2+, Ni2+, Zn2+).
- Employed pH gradients for peptide elution and recovery.
Main Results:
- A beta(1-42) and fragments showed differential retention on Cu(II), Ni(II), and Zn(II) columns.
- Irreversible binding of A beta peptides to IDA-Cu(II) was observed.
- A beta peptides were recovered from IDA-Ni(II) between pH 5.1-5.6.
- Differential retention on IDA-Zn(II) was observed based on peptide length and pH.
Conclusions:
- Histidine clusters in A beta peptides are high-affinity binding sites for immobilized metal chelates.
- IMAC demonstrates potential for selective separation of A beta peptides.
- The findings contribute to understanding A beta peptide interactions and developing IMAC-based analytical methods.
More Related Videos
Related Concept Videos
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
03:03Amyloid Fibrils
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
01:22EDTA: Chemistry and Properties
Polydentate ligands are most widely used in complexometric titrations because they form more stable complexes with the metal ions than mono- or bidentate ligands due to the chelate effect. Examples of polydentate ligands are ethylenediaminetetraacetic acid (EDTA), crown ethers, and cryptands. The most important feature of optimal polydentate ligands is the ability to form 1:1 complexes in a single-step process. Amino carboxylic acid derivatives are frequently used as complexing agents. EDTA is...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...